The application of natural products has long been used in
the treatment of illness and disease, many of which formed the industrial
inspiration to develop from pharmacognosy into active pharmaceuticals.
Resveratrol is a common phytochemical found in abundance in nutritious and
wholesome foods and thus has likely been part of the human diet for many
centuries. As such, resveratrol may contribute to the success of the French
Paradox, where the inclusion of red wines is a familiar dietary addition and is
associated with reduced incidence of cardiovascular disease. The primary
metabolic action of resveratrol and related phenolic compounds likely rests in
its potential antioxidant activity, being able to quench reactive free radicals
(ROS) and other inflammatory activities in peripheral tissues. Resveratrol has
been suggested as an adjunct in the clinical management of numerous metabolic
disorders, including diabetes, obesity, hypertension, pre-eclampsia, and sickle
cell disease, among others associated with chronic inflammation. Thus, the
purpose of this review is to examine the safety and efficacy of resveratrol in
pregnancy. This review also discusses the biochemical, pharmacologic and
potential toxicologic aspects of trans-resveratrol administration as an adjunct
in the treatment of hemoglobinopathies, including Sickle cell disease (SCD),
during pregnancy. SCD represents a serious complication of normal pregnancy
with few successful treatments, as the change in amino acid charge alters the
protein’s hydrophobic structure and function. When present, it can result in
the abnormal polymerisation to form deoxy-HbS and sickling, particularly during
physiologic processes that incur high oxygen demand, including later stages of
gestation and parturition. The results
indicate that resveratrol is likely a safe and effective adjunct in treating
the hypoxia and chronic inflammation of pregnancy, in addition to its
applications in various hemoglobinopathies, including sickle cell disease, by
inducing increased production of sickle-resistant fetal haemoglobin (HbF) in
addition to reducing the magnitude of chronic inflammation, while enhancing
oxygen delivery to peripheral tissues via actions of fetal haemoglobin. Thus,
RSV may also be able to partially correct the effects linked to the globin
chain imbalance in SCD patients, while at the same time facilitating oxygen
transport to myoglobin in peripheral tissues due to a more favourable
oxygen-delivering capacity than is observed in adult haemoglobin.
Author(s) Details
Orien L Tulp
University of Science Arts and Technology, Montserrat, Colleges of Medicine
and Graduate Studies, Spain, The Einstein Medical Institute, North Palm Beach,
Florida, USA, East West College of Natural Medicine, Sarasota, FL, USA and
Universidad de Sevilla, Seville, Spain.
Frantz Sainvil
University of Science Arts and Technology, Montserrat, Colleges of Medicine
and Graduate Studies, Spain, The Einstein Medical Institute, North Palm Beach,
Florida, USA and Broward College, Davie, FL, USA.
Uzoamaka Nwokorie
University of Science Arts and Technology, Montserrat, Colleges of Medicine
and Graduate Studies, Spain.
George P Einstein
University of Science Arts and Technology, Montserrat, Colleges of Medicine
and Graduate Studies, Spain and The Einstein Medical Institute, North Palm
Beach, Florida, USA
Please see the book here :- https://doi.org/10.9734/bpi/aodhr/v5/6062
No comments:
Post a Comment